medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2019, Number 2

<< Back Next >>

Rev Mex Urol 2019; 79 (2)

Urinary tract infections caused by extended spec-trum beta-lactamase-producing Escherichia coli at a Spanish tertiary care hospital

Barrios-Arnau L, Sanchez-Llopis A, Ponce-Blasco P, Gomila SB, Monsonis UR, Barrios-Arnau M, Capua-Sacoto CD

Language: Spanish
References: 18
Page: 1-8
PDF size: 170.37 Kb.


ABSTRACT

Background: The aim of the present study was to evaluate the isolation of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) strains in patients with urinary tract infections.
Materials and methods: A retrospective study was conducted on patients seen at the Departamento de Salud de Castellón, Spain, within the time frame of January 2012 to December 2016, whose urine cultures were positive for E. coli. The following variables were analyzed: age, sex, type of patient (outpatient or hospitalized), and risk factors. The prevalence of ESBL-producing E. coli was determined through a descriptive analysis. The statistical analysis was carried out utilizing the SPSS 18.0 program. The quantitative variables were analyzed using the Student’s t test and the qualitative variables with the chi-square test.
Results: A total of 11,740 cultures were obtained that were positive for E. coli and 446 (3.79%) of them had the ESBL-producing E. coli strains. The percentage per year of ESBL-producing E. coli infection ranged from 1.7% to 6.5%, showing an increasing trend in the isolation of the resistant strains in more recent years. Mean patient age was 68.9 years, and there were no differences between the sexes. A total of 350 cultures corresponded to outpatients (78.7%), 70.5% of whom were women. The risk factors most associated with ESBL were: having presented with a urinary tract infection (UTI) within the past year and having received antibiotic treatment within the previous 3 months. Fifty percent of the patients that had received an antibiotic had been given a beta-lactam.
Conclusions: The isolation of ESBL-producing E. coli strains was similar to that found in other case series. There was an increase in the prevalence of those difficult-to-treat infections. The majority of the patients were outpatients, had previously been treated with antibiotics, and presented with recurrent UTIs.


REFERENCES

  1. García-Hernández AM, García-Vázquez E, Hernández-Torres A, Ruiz J, Yagüe G, Herrero JA, et al. Bacteriemias por Escherichia coli productor de betalactamasas de espectro extendido (blee): significación clínica y perspectivas actuales. Rev Esp Quimioter. 2011;24(2):57–66.

  2. Andreu A, Planells I, los Patógenos Urinario GCE para el E de la SA de. Etiología de la infección urinaria baja adquirida en la comunidad y resistencia de Escherichia coli a los antimicrobianos de primera línea. Estudio nacional multicéntrico. Med Clin (Barc). 2008;130(13):481–6. [accessed 5 Jun 2019] Available from: http://www.elsevier.es/esrevista- medicina-clinica-2-articulo-etiologiainfeccion- urinaria-baja-adquirida-13119488

  3. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122(6):7–15. doi: https://doi. org/10.3810/pgm.2010.11.2217

  4. O’Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. BMC Infect Dis. 2016;16(1):620. doi: https:// doi.org/10.1186/s12879-016-1797-3

  5. de Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual Á. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin. 2006;24(10):613–6. [accessed 5 Jun 2019] Available from: http://www.sciencedirect.com/ science/article/pii/S0213005X06738782

  6. García-Tello A, Gimbernat H, Redondo C, Arana DM, Cacho J, Angulo JC. Betalactamasas de espectro extendido en las infecciones del tracto urinario causadas por enterobacterias: aproximación a su conocimiento y pautas de actuación. Actas Urol Esp. 2014;38(10):678–84. [accessed 5 Jun 2019] Available from: http:// www.sciencedirect.com/science/article/pii/ S0210480614001843

  7. Martin D, Fougnot S, Grobost F, Thibaut-Jovelin S, Ballereau F, Gueudet T, et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect. 2016;72(2):201–6. doi: https://doi. org/10.1016/j.jinf.2015.11.009

  8. Fernando MMPSC, Luke W a. NV, Miththinda JKND, Wickramasinghe RDSS, Sebastiampillai BS, Gunathilake MPML, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study. BMC Infect Dis. 2017;17(1):138. doi: https://doi.org/10.1186/ s12879-017-2250-y

  9. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–63. doi: https://doi. org/10.1086/650482

  10. Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007;29(10):2215–21. doi: https://doi. org/10.1016/j.clinthera.2007.10.008

  11. Aguilar-Duran S, Horcajada JP, Sorlí L, Montero M, Salvadó M, Grau S, et al. Community- onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections. J Infect. 2012;64(5):478–83. doi: https://doi. org/10.1016/j.jinf.2012.01.010

  12. Bidell MR, Opraseuth MP, Yoon M, Mohr J, Lodise TP. Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections. BMC Infect Dis. 2017;17(1):176. doi: https://doi.org/10.1186/s12879-017-2270-7

  13. Chavolla-Canal AJ, González-Mercado MG. Factores de riesgo asociados con infección de la vía urinaria provocada por superbacterias. Rev Mex Urol. 2018;78(6):425–33.

  14. Salame-Khouri L, Contreras-Pichardo B, Arias-Rodríguez S, Mondragón-Soto M, Cataneo-Serrato JL, Núñez-Martínez M, et al. Epidemiología de las bacteriemias por Escherichia coli en dos hospitales de tercer nivel de la Ciudad de México. An Med Asoc Med Hosp ABC. 2018;63(2):91–5.

  15. Picozzi S, Ricci C, Gaeta M, Macchi A, Dinang E, Paola G, et al. Do we really know the prevalence of multi-drug resistant Escherichia coli in the territorial and nosocomial population? Urol Ann. 2013;5(1):25–9. [accessed 5 Jun 2019] Available from: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3643319/

  16. World Health Organization. WHO | Antimicrobial resistance: global report on surveillance 2014. Paris: World Health Organization; 2014. 257 p. [accessed 5 Jun 2019] Available from: http://www.who.int/drugresistance/documents/ surveillancereport/en/

  17. Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16(2):147–51. doi: https://doi. org/10.1111/j.1469-0691.2009.02941.x

  18. Silva-Sanchez J, Garza-Ramos JU, Reyna- Flores F, Sánchez-Perez A, Rojas-Moreno T, Andrade-Almaraz V, et al. Extended-spectrum β-lactamase-producing enterobacteriaceae causing nosocomial infections in Mexico. A retrospective and multicenter study. Arch Med Res. 2011;42(2):156–62. doi: https://doi. org/10.1016/j.arcmed.2011.02.004




2020     |     www.medigraphic.com